Devazepide

Devazepide

SCHEMBL148766

CN1C(=O)[C@@H](NC(=O)c2cc3ccccc3[nH]2)N=C(c2ccccc2)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCKBR P32239 16/20 1.00
CCKAR P32238 13/20 1.00
ADRB2 P07550 1/20 1.00
TSPO P30536 1/20 1.00
GLP1R P43220 1/20 1.00
FFAR4 Q5NUL3 1/20 1.00
PDE4A P27815 2/20 0.64
PDE4B Q07343 2/20 0.64
PDE4C Q08493 2/20 0.64
PDE4D Q08499 2/20 0.64
PDE5A O76074 1/20 0.64
PDE1A P54750 1/20 0.64
PDE1B Q01064 1/20 0.64
PDE1C Q14123 1/20 0.64
GABRP O00591 1/20 0.62
GABRD O14764 1/20 0.62
GABRA1 P14867 1/20 0.62
GABRB1 P18505 1/20 0.62
GABRG2 P18507 1/20 0.62
GABRB3 P28472 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Devazepide SCHEMBL4884074 1.00 CCKBR (1.00) CCKBRCCKARADRB2TSPOGLP1R
Devazepide SCHEMBL6255769 1.00 CCKBR (1.00) CCKBRCCKARADRB2TSPOGLP1R
Devazepide SCHEMBL29406251 1.00 CCKBR (1.00) CCKBRCCKARADRB2TSPOGLP1R
Devazepide SCHEMBL31616311 1.00 CCKBR (1.00) CCKBRCCKARADRB2TSPOGLP1R
Devazepide SCHEMBL8613468 1.00 CCKBR (1.00) CCKBRCCKARADRB2TSPOGLP1R
SCHEMBL8437864 0.94 CCKBR (0.88) CCKBRCCKARADRB2TSPOGLP1R
SCHEMBL9842437 0.94 CCKBR (0.88) CCKBRCCKARADRB2TSPOGLP1R
SCHEMBL9422963 0.91 CCKBR (0.83) CCKBRCCKARADRB2TSPOGLP1R
SCHEMBL7143510 0.90 CCKBR (0.82) CCKBRCCKARADRB2TSPOGLP1R
SCHEMBL7143513 0.90 CCKBR (0.82) CCKBRCCKARADRB2TSPOGLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186634-A1 METHODS OF TREATING SMALL CELL LUNG CANCER Evergreen Discovery, LLC (US) 2025-06-12 US claimed
WO-2025122363-A2 METHODS OF TREATING SMALL CELL LUNG CANCER Evergreen Discovery, LLC (US) 2025-06-12 WO claimed
US-20250082649-A1 ALTERATION OF NUTRIENT PREFERENCES VIA MODULATION OF NUTRIENT RECEPTORS IN THE GUT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2025-03-13 US claimed
WO-2024256731-A2 A CHOLECYSTOKININ (CCK) ANTAGONIST FOR USE IN THE PREVENTION AND/OR TREATMENT OF A VESTIBULAR DISEASE OR DISORDER UNIVERSITAT AUTONOMA DE BARCELONA (ES) 2024-12-19 WO claimed
EP-4477218-A1 A CHOLECYSTOKININ (CCK) ANTAGONIST FOR USE IN THE PREVENTION AND/OR TREATMENT OF A VESTIBULAR DISEASE OR DISORDER Universitat Autònoma de Barcelona (ES) 2024-12-18 EP claimed
WO-2023164661-A1 ALTERATION OF NUTRIENT PREFERENCES VIA MODULATION OF NUTRIENT RECEPTORS IN THE GUT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-08-31 WO claimed
WO-2019018438-A1 COMPOSITIONS AND METHODS FOR THE MODULATION OF GUT SENSORY CELLS DUKE UNIVERSITY (US) 2019-01-24 WO claimed
CN-105687203-B Application of cholecystokinin receptor inhibitor Devazepide in preparation of anti-fibrosis pharmaceutical preparation 无锡市人民医院 2018-07-10 CN claimed
CN-105687203-A Application of cholecystokinin receptor inhibitor Devazepide in preparation of anti-fibrosis pharmaceutical preparation 无锡市人民医院 2016-06-22 CN claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
EP-1023072-B1 ANALGESIC COMPOSITIONS COMPRISING A CHOLECYSTOKININ AND AN OPIOID PANOS THERAPEUTICS LTD (GB) 2002-12-11 EP claimed
EP-0730453-A4 METHODS OF TREATING CARDIAC ARRHYTHMIA MERCK & CO INC (US) 1998-03-04 EP claimed
EP-0730453-A1 METHODS OF TREATING CARDIAC ARRHYTHMIA MERCK & CO. INC. (US) 1996-09-11 EP claimed
US-5428031-A Benzodiazepine analogs; cardiovascular disorders MERCK & CO., INC. (US) 1995-06-27 US claimed
WO-1995014470-A1 METHODS OF TREATING CARDIAC ARRHYTHMIA MERCK & CO., INC. (US) 1995-06-01 WO claimed
EP-0167919-B1 BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM MERCK & CO. INC. (US) 1993-05-05 EP claimed
WO-1993003717-A1 CHOLECYSTOKININ ANTAGONISTS USEFUL FOR TREATING DEPRESSION WARNER-LAMBERT COMPANY (US) 1993-03-04 WO claimed
US-5153191-A Administering lorglumide or loxiglumide or salts thereof WARNER-LAMBERT COMPANY (US) 1992-10-06 US claimed
EP-0284256-A1 Benzodiazepine analogs MERCK & CO. INC. (US) 1988-09-28 EP claimed
EP-0167919-A2 Benzodiazepine derivatives and pharmaceutical compositions containing them MERCK & CO. INC. (US) 1986-01-15 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186634-A1 METHODS OF TREATING SMALL CELL LUNG CANCER SSTR2, CCKBR, GRPR CCKBR 2/4885CCKAR 4/4885ADRB2 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.